Ren Zheng-gang, Gan Yu-hong, Fan Jia, Chen Yi, Wu Zhi-quan, Qin Lun-xiu, Ge Ning-ling, Zhou Jian, Xia Jing-lin, Wang Yan-hong, Ye Qing-hai, Wang Lu, Ye Sheng-long
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhonghua Wai Ke Za Zhi. 2008 Nov 1;46(21):1614-6.
To evaluate the efficacy of radiofrequency ablation for the treatment of postoperative recurrence of hepatocellular carcinoma and whether radiofrequency ablation can be used as first line treatment for recurrent hepatocellular carcinoma.
There were 213 patients with small recurrent hepatocellular carcinoma (tumor size of 3 cm or less and no more than 3 nodules) who treated in Liver Cancer Institute, Fudan University from January 2000 to December 2005. Among these patients 68 were treated with radiofrequency ablation and 145 were treated with repeated surgical resection. Kaplan-Meier method was used to evaluate the overall survival or disease free survival. Log-rank used to determine the survival difference between groups and COX proportional hazard was used for multivariate analysis to evaluate the risk factors for prognosis. The overall survival or disease free survival was calculated from the time treated with radiofrequency or repeated surgical resection.
The 1-, 3-, 5-years overall survival rates were 94.7%, 65.1%, 37.3% and 88.1%, 62.6%, 41.0% in radiofrequency ablation group and surgical repeated resection group, respectively. There was no significant difference between two groups (P = 0.693). However, the disease free survival was better in repeated surgical resection than in radiofrequency ablation, which were 79.4%, 48.1%, 34.4% and 58.0%, 27.8%, 12.4% in repeated surgical resection and radiofrequency ablation, respectively (P = 0.001). The interval between recurrence and initial hepatectomy with more than 2 years was independent factor favor to good prognosis.
Radiofrequency ablation seems to be as effective as repeated surgical resection owing to comparable overall survival and can be considered as alternative therapy for surgical resection treatment of small recurrent hepatocellular carcinoma.
评估射频消融治疗肝细胞癌术后复发的疗效,以及射频消融是否可作为复发性肝细胞癌的一线治疗方法。
选取2000年1月至2005年12月在复旦大学肝癌研究所治疗的213例小复发性肝细胞癌患者(肿瘤大小为3 cm或更小且结节不超过3个)。其中68例接受射频消融治疗,145例接受再次手术切除。采用Kaplan-Meier法评估总生存期或无病生存期。用Log-rank检验确定组间生存差异,并用COX比例风险模型进行多因素分析以评估预后的危险因素。总生存期或无病生存期从接受射频消融或再次手术切除治疗的时间开始计算。
射频消融组和再次手术切除组的1年、3年、5年总生存率分别为94.7%、65.1%、37.3%和88.1%、62.6%、41.0%。两组之间无显著差异(P = 0.693)。然而,再次手术切除组的无病生存期优于射频消融组,再次手术切除组和射频消融组的无病生存期分别为79.4%、48.1%、34.4%和58.0%、27.8%、12.4%(P = 0.001)。复发与初次肝切除间隔超过2年是有利于良好预后的独立因素。
由于总生存期相当,射频消融似乎与再次手术切除一样有效,可被视为小复发性肝细胞癌手术切除治疗的替代疗法。